AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.694
+0.053 (8.33%)
Mar 6, 2026, 4:00 PM EST - Market closed
AIM ImmunoTech Employees
As of December 31, 2024, AIM ImmunoTech had 23 total employees, including 21 full-time and 2 part-time employees. The number of employees decreased by 5 or -17.86% compared to the previous year.
Employees
23
Change (1Y)
-5
Growth (1Y)
-17.86%
Revenue / Employee
$4,870
Profits / Employee
-$684,783
Market Cap
2.93M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| Scinai Immunotherapeutics | 31 |
| Calidi Biotherapeutics | 28 |
| Azitra | 12 |
| Dermata Therapeutics | 8 |
| Enveric Biosciences | 6 |
| Acurx Pharmaceuticals | 4 |
| XORTX Therapeutics | 3 |
AIM News
- 13 hours ago - AIM ImmunoTech Announces Closing of its Rights Offering - GlobeNewsWire
- 4 days ago - AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer - GlobeNewsWire
- 7 days ago - AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - GlobeNewsWire
- 11 days ago - AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 22 days ago - CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewsWire
- 24 days ago - AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewsWire
- 25 days ago - Aimia Inc. (AIM:CA) M&A Call Transcript - Seeking Alpha
- 4 weeks ago - AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - GlobeNewsWire